Sign In
Buy AORT
$24.03
-0.0600 (-0.249%)
At Close: Jul 13, 2026
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
11:16am, Wednesday, 01'st Jul 2026
AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion
09:30am, Tuesday, 30'th Jun 2026
Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute aortic dissection. AMDS's clinical data shows reduced mortality and major adve
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis
07:00am, Monday, 29'th Jun 2026
ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administratio
Artivion to Participate in the 2026 Truist Securities MedTech Conference
04:10pm, Wednesday, 10'th Jun 2026
ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
08:00am, Monday, 18'th May 2026
Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to ac
Endospan Announces Closing of Acquisition by Artivion, Inc., Following FDA PMA Approval of the NEXUS® Aortic Arch System
07:05am, Monday, 18'th May 2026
HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction
Artivion Completes Acquisition of Endospan Ltd.
07:00am, Monday, 18'th May 2026
ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing
Crafting title options within editorial guidelines An ETF Shop Just Made a Beaten-Down Medtech Its Top Holding
04:31pm, Sunday, 17'th May 2026
Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
Shareholder Alert: Ademi LLP Investigates Claims of Securities Fraud against Artivion, Inc.
11:30am, Monday, 11'th May 2026
MILWAUKEE, May 11, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Artivion (NYSE: AORT). The investigation results from inaccurate statements Artivion may ha
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
03:07pm, Sunday, 10'th May 2026
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion Q1 Earnings Call Highlights
07:06am, Saturday, 09'th May 2026
Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily
Artivion (AORT) Q1 Earnings and Revenues Surpass Estimates
08:11pm, Thursday, 07'th May 2026
Artivion (AORT) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.06 per share a year ago.
Artivion Reports First Quarter 2026 Financial Results and Announces Exercise of Option to Acquire Endospan
04:05pm, Thursday, 07'th May 2026
First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter of 2025, an increase of 18% on a GAAP basis and 12
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results
04:15pm, Thursday, 23'rd Apr 2026
ATLANTA, April 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2026 financial results
Head-To-Head Comparison: Pressure BioSciences (OTCMKTS:PBIO) and Artivion (NYSE:AORT)
01:26am, Monday, 13'th Apr 2026
Pressure BioSciences (OTCMKTS:PBIO - Get Free Report) and Artivion (NYSE: AORT - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two compan
